Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Ferris, Robert L., Licitra, Lisa, Fayette, Jerome, Even, Caroline, Blumenschein, George, Harrington, Kevin J., Guigay, Joel, Vokes, Everett E., Saba, Nabil F., Haddad, Robert, Ramkumar, Shanmugasundaram, Russell, Jeffery, Brossart, Peter, Tahara, Makoto, Colevas, A. Dimitrios, Concha-Benavente, Fernando, Lynch, Mark, Li, Li, Gillison, Maura L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7721346/
https://ncbi.nlm.nih.gov/pubmed/31239321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3944
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares